No more machines and no more outsource testing, is the direction the British biotech firm Sense Biodetection is headed, and they now have £12.3million of venture capital funding behind them.

Sense is a start-up biotech company based in Oxfordshire, UK, which was founded by molecular scientist Harry Lamble and his brother Ralph, a design engineer. They aim to speed up diagnosis so that a test can be made by a patient’s bedside or in the surgery and results obtained within minutes. Their primary focus is on diagnosing infectious diseases and oncology indications.

The company has raised £10.5m Series A investment co-led by Cambridge Innovation Capital (CIC) and Earlybird, with participation from Jonathan Milner and seed round investor Mercia Asset Management. Concurrent with the investment, Sense has also secured a grant of £1.8m from Innovate UK.

Sense opened a development facility near Cambridge in 2017, which conveniently places the company in between the UK’s two leading university cities, which provides Sense with “unrivaled access to the expertise and talent needed to support the Company’s future growth,” states CDO Ralph Lamble.

Last year Sense appointed Dr. Gemma Blackwell as Principal Scientist, who has already been involved in the development of molecular diagnostics through to receiving CE marking.